Most Recent
Regenerative medicine company Mesoblast has been hit with a second class action for allegedly misleading shareholders about it Remestemcel-L treatment for COVID-19 complications.
The litigation funder backing two combustible cladding class actions has sold a third of its investment in the cases to a player in the nascent secondary market for class action financing.
A unit of Suncorp Group has reached an in-principle settlement in a class action over alleged conflicted remuneration on the first day of an expected 25-day trial.
The applicants in a class action against The Cosmetic Institute and twelve doctors over allegedly "incompetent" breast augmentation surgery have won court approval to expand their case to allege misleading and deceptive conduct and breaches of the consumer guarantees in the Australian Consumer Law.
Regenerative medicine company Mesoblast is facing another class action over claims it misled shareholders about the potential application of a developmental stem cell product to treat terminally ill children.
Bill Papas’ girlfriend Louise Agostino has hit back at Westpac’s lawsuit accusing her of involvement in the Forum Group director’s alleged $294 million fraud, denying all allegations and arguing that the bulk of the bank’s claims against her should be struck out.
A lawyer for Forum Finance director Bill Papas has argued the alleged fraudster should be able to shield documents held by his former lawyer under a claim for legal professional privilege despite being a “fugitive” from contempt charges.
Car repair giant AMA Group may have a discovery fight on its hands in its lawsuit against former boss Andrew Hopkins for allegedly defrauding the company of $3 million.
An appeals court has found that Avant Insurance must indemnify a plastic surgeon for his legal bills and the claims of all relevant group members in a class action over alleged botched breast augmentations.
A judge hearing a superannuation class action against NAB unit NULIS Nominees will not determine the correct approach for calculating damages at an initial trial scheduled for later this year.